Unum Therapeutics (UMRX) Investor Presentation - Slideshow

Platform and Pipeline - Unum Therapeutics' ACTR/BOXR platforms are designed to improve targeting and functionality of T cell therapies[5,8] - The company is advancing a pipeline of product candidates in hematologic cancers and solid tumors, including ACTR707, ACTR087, and BOXR1030[6] - BOXR platform addresses the tumor microenvironment (TME) challenge by improving T cell functionality[14,15] Clinical Trial Results (ACTR707 in r/r NHL) - Preliminary Phase 1 trial data for ACTR707 in relapsed/refractory (r/r) Non-Hodgkin's Lymphoma (NHL) showed an overall response rate (ORR) of 64% (9/14 patients) across Cohorts 1-3[25] - Complete responses (CR) were observed in 36% of patients (5/14) across Cohorts 1-3[25] - The trial showed a favorable safety profile with no dose-limiting toxicities (DLTs), severe neurologic events, or Cytokine Release Syndrome (CRS) observed in Cohorts 1-3[27] Clinical Trial Results (ACTR087 in Multiple Myeloma) - Phase 1 trial of ACTR087 in multiple myeloma completed three dose levels in 2018 at very low antibody doses and 30M ACTR+ T cells, with no dose-limiting toxicities or severe CRS or neurologic events observed[33] Solid Tumor Programs - ACTR707 is also being evaluated in a Phase 1 trial for advanced HER2+ cancers[6,37] - BOXR1030, a GPC3-targeted CAR-T, is engineered for enhanced metabolism in the solid tumor microenvironment and has shown promising preclinical activity[39,42] Upcoming Milestones - Several milestones are anticipated in 4Q 2019, including reporting preliminary Cohort 3 results and Cohort 1-4 results from ATTCK-20-03, reporting safety and efficacy results from Phase 1 (ATTCK-20-02), reporting enrollment status and safety in Phase 1 (ATTCK-34-01), progress BOXR-1030 towards IND[43]